Brief: Codiak Initiates Patient Dosing In Phase 1 Clinical Trial Of Exoaso-Stat6 In Patients With Advanced Hepatocellular Carcinoma, Liver Metastases From Primary Gastric Cancer And Colorectal Cancer
29/06/2022 13:03
June 29 (Reuters) - Codiak BioSciences, Inc. CDAK.O :
* CODIAK INITIATES PATIENT DOSING IN PHASE 1 CLINICAL TRIAL
OF
EXOASO™-STAT6 IN PATIENTS WITH ADVANCED HEPATOCELLULAR
CARCINOMA, LIVER METASTASES FROM PRIMARY GASTRIC CANCER AND
COLORECTAL CANCER
Source text for Eikon: ID:nGNXbBt1Jn
Further company coverage: CDAK.O
Recent news on Codiak BioSciences,.
See all newsBrief: Codiak Biosciences Notice From Listing Qualifications Department Of Nasdaq Trading Of Co's Common Stock To Be Suspended At Opening Of Business On April 5
U.S. STOCKS ON THE MOVE-Energy firms, crypto stocks, Walt Disney
U.S. STOCKS ON THE MOVE-Cyclerion, banks, Jounce Therapeutics
U.S. STOCKS ON THE MOVE-Tesla, BrainStorm, Pinterest
Codiak BioSciences down after co files for Chapter 11 bankruptcy